Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Cancer. 2012 Jan 17;118(17):4354–4362. doi: 10.1002/cncr.26734

FIGURE 1.

FIGURE 1

A flow diagram outlining the patient population participating in the clinical trial. Of the 38 patients eligible for the trial, 27 patients gave written informed consent and enrolled on the IRB-approved trial. Five patients had no residual disease following vaccination while 22 patients had residual disease thus allowing for analysis of post-vaccine immune response.